Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma
We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreov...
Gespeichert in:
| Veröffentlicht in: | Cancer biology & therapy 2024-12, Vol.25 (1), p.2365449 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2365449 |
| container_title | Cancer biology & therapy |
| container_volume | 25 |
| creator | Yang, Xuewen Li, Shisen Xu, Chunsheng Liu, Shushang Zhang, Xiang Lian, Bo Li, Mengbin |
| description | We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced in vivo ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity. |
| doi_str_mv | 10.1080/15384047.2024.2365449 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11174053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_dfa44998f9694b6ba2e85c2352a75f53</doaj_id><sourcerecordid>3067915152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-2bdaff7f92b34fd8f154731fd11a5784fca02560204e43974ce7550619b8a3633</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhSMEoqXwCCAvy2IG_ybOClDFT6VKLIC1dePYM66cOLWdVnkHHhqnM63ohpWv7O-ca1-fqnpL8JZgiT8QwSTHvNlSTPmWslpw3j6rTokQYiNFUz9fayY3K3RSvUrpGmPa0Lp9WZ0wKWtBanJa_fnpYp7dSNB5KhV5j6LZzR6ySSjvDdr5RQe_JJfQBHl_BwuCsUe90dFAKpB2aSq4G5HemyEUTYTJzNlplMyYXHa3Li8oB2RSmPawM-BRuplhCHNRG--RhqjdGAZ4Xb2w4JN5c1zPqt9fv_y6-L65-vHt8uLz1UZzyfKGdj1Y29iWdozbXloieMOI7QkB0UhuNWAqakwxN5y1DdemEQLXpO0ksJqxs-ry4NsHuFZTdAPERQVw6n4jxJ2CWF7gjeotlLm20rZ1y7u6A2qk0JQJCo2wYvX6ePCa5m4wvTZjjuCfmD49Gd1e7cKtIoQ0HN87nB8dYriZTcpqcGkdDIymzEgxXDctEUTQgooDqmNIKRr72IdgtcZCPcRCrbFQx1gU3bt_L_moeshBAT4dADfaEAe4C9H3KsPiQ7QRxvLLiv2_x1-kV8rO</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3067915152</pqid></control><display><type>article</type><title>Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yang, Xuewen ; Li, Shisen ; Xu, Chunsheng ; Liu, Shushang ; Zhang, Xiang ; Lian, Bo ; Li, Mengbin</creator><creatorcontrib>Yang, Xuewen ; Li, Shisen ; Xu, Chunsheng ; Liu, Shushang ; Zhang, Xiang ; Lian, Bo ; Li, Mengbin</creatorcontrib><description>We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced in vivo ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity.</description><identifier>ISSN: 1538-4047</identifier><identifier>ISSN: 1555-8576</identifier><identifier>EISSN: 1555-8576</identifier><identifier>DOI: 10.1080/15384047.2024.2365449</identifier><identifier>PMID: 38865161</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Cell Line, Tumor ; chemosensitivity ; cisplatin ; Cisplatin - pharmacology ; Cisplatin - therapeutic use ; Drug Resistance, Neoplasm - genetics ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - genetics ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - pathology ; Esophageal squamous cell carcinoma ; Esophageal Squamous Cell Carcinoma - drug therapy ; Esophageal Squamous Cell Carcinoma - genetics ; Esophageal Squamous Cell Carcinoma - metabolism ; Esophageal Squamous Cell Carcinoma - pathology ; Female ; glycolysis ; Glycolysis - drug effects ; Humans ; Male ; Mice ; Mice, Nude ; Research Paper ; sirt1 ; Sirtuin 1 - genetics ; Sirtuin 1 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer biology & therapy, 2024-12, Vol.25 (1), p.2365449</ispartof><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024</rights><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c483t-2bdaff7f92b34fd8f154731fd11a5784fca02560204e43974ce7550619b8a3633</cites><orcidid>0000-0003-4946-4618</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174053/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174053/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,27483,27905,27906,53772,53774,59122,59123</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38865161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Xuewen</creatorcontrib><creatorcontrib>Li, Shisen</creatorcontrib><creatorcontrib>Xu, Chunsheng</creatorcontrib><creatorcontrib>Liu, Shushang</creatorcontrib><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Lian, Bo</creatorcontrib><creatorcontrib>Li, Mengbin</creatorcontrib><title>Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma</title><title>Cancer biology & therapy</title><addtitle>Cancer Biol Ther</addtitle><description>We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced in vivo ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Line, Tumor</subject><subject>chemosensitivity</subject><subject>cisplatin</subject><subject>Cisplatin - pharmacology</subject><subject>Cisplatin - therapeutic use</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - genetics</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal squamous cell carcinoma</subject><subject>Esophageal Squamous Cell Carcinoma - drug therapy</subject><subject>Esophageal Squamous Cell Carcinoma - genetics</subject><subject>Esophageal Squamous Cell Carcinoma - metabolism</subject><subject>Esophageal Squamous Cell Carcinoma - pathology</subject><subject>Female</subject><subject>glycolysis</subject><subject>Glycolysis - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Research Paper</subject><subject>sirt1</subject><subject>Sirtuin 1 - genetics</subject><subject>Sirtuin 1 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1538-4047</issn><issn>1555-8576</issn><issn>1555-8576</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9ks1u1DAUhSMEoqXwCCAvy2IG_ybOClDFT6VKLIC1dePYM66cOLWdVnkHHhqnM63ohpWv7O-ca1-fqnpL8JZgiT8QwSTHvNlSTPmWslpw3j6rTokQYiNFUz9fayY3K3RSvUrpGmPa0Lp9WZ0wKWtBanJa_fnpYp7dSNB5KhV5j6LZzR6ySSjvDdr5RQe_JJfQBHl_BwuCsUe90dFAKpB2aSq4G5HemyEUTYTJzNlplMyYXHa3Li8oB2RSmPawM-BRuplhCHNRG--RhqjdGAZ4Xb2w4JN5c1zPqt9fv_y6-L65-vHt8uLz1UZzyfKGdj1Y29iWdozbXloieMOI7QkB0UhuNWAqakwxN5y1DdemEQLXpO0ksJqxs-ry4NsHuFZTdAPERQVw6n4jxJ2CWF7gjeotlLm20rZ1y7u6A2qk0JQJCo2wYvX6ePCa5m4wvTZjjuCfmD49Gd1e7cKtIoQ0HN87nB8dYriZTcpqcGkdDIymzEgxXDctEUTQgooDqmNIKRr72IdgtcZCPcRCrbFQx1gU3bt_L_moeshBAT4dADfaEAe4C9H3KsPiQ7QRxvLLiv2_x1-kV8rO</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Yang, Xuewen</creator><creator>Li, Shisen</creator><creator>Xu, Chunsheng</creator><creator>Liu, Shushang</creator><creator>Zhang, Xiang</creator><creator>Lian, Bo</creator><creator>Li, Mengbin</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4946-4618</orcidid></search><sort><creationdate>20241231</creationdate><title>Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma</title><author>Yang, Xuewen ; Li, Shisen ; Xu, Chunsheng ; Liu, Shushang ; Zhang, Xiang ; Lian, Bo ; Li, Mengbin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-2bdaff7f92b34fd8f154731fd11a5784fca02560204e43974ce7550619b8a3633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Line, Tumor</topic><topic>chemosensitivity</topic><topic>cisplatin</topic><topic>Cisplatin - pharmacology</topic><topic>Cisplatin - therapeutic use</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - genetics</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal squamous cell carcinoma</topic><topic>Esophageal Squamous Cell Carcinoma - drug therapy</topic><topic>Esophageal Squamous Cell Carcinoma - genetics</topic><topic>Esophageal Squamous Cell Carcinoma - metabolism</topic><topic>Esophageal Squamous Cell Carcinoma - pathology</topic><topic>Female</topic><topic>glycolysis</topic><topic>Glycolysis - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Research Paper</topic><topic>sirt1</topic><topic>Sirtuin 1 - genetics</topic><topic>Sirtuin 1 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Xuewen</creatorcontrib><creatorcontrib>Li, Shisen</creatorcontrib><creatorcontrib>Xu, Chunsheng</creatorcontrib><creatorcontrib>Liu, Shushang</creatorcontrib><creatorcontrib>Zhang, Xiang</creatorcontrib><creatorcontrib>Lian, Bo</creatorcontrib><creatorcontrib>Li, Mengbin</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Cancer biology & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Xuewen</au><au>Li, Shisen</au><au>Xu, Chunsheng</au><au>Liu, Shushang</au><au>Zhang, Xiang</au><au>Lian, Bo</au><au>Li, Mengbin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma</atitle><jtitle>Cancer biology & therapy</jtitle><addtitle>Cancer Biol Ther</addtitle><date>2024-12-31</date><risdate>2024</risdate><volume>25</volume><issue>1</issue><spage>2365449</spage><pages>2365449-</pages><issn>1538-4047</issn><issn>1555-8576</issn><eissn>1555-8576</eissn><abstract>We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced in vivo ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>38865161</pmid><doi>10.1080/15384047.2024.2365449</doi><orcidid>https://orcid.org/0000-0003-4946-4618</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1538-4047 |
| ispartof | Cancer biology & therapy, 2024-12, Vol.25 (1), p.2365449 |
| issn | 1538-4047 1555-8576 1555-8576 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11174053 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Line, Tumor chemosensitivity cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Drug Resistance, Neoplasm - genetics Esophageal Neoplasms - drug therapy Esophageal Neoplasms - genetics Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Esophageal squamous cell carcinoma Esophageal Squamous Cell Carcinoma - drug therapy Esophageal Squamous Cell Carcinoma - genetics Esophageal Squamous Cell Carcinoma - metabolism Esophageal Squamous Cell Carcinoma - pathology Female glycolysis Glycolysis - drug effects Humans Male Mice Mice, Nude Research Paper sirt1 Sirtuin 1 - genetics Sirtuin 1 - metabolism Xenograft Model Antitumor Assays |
| title | Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T13%3A35%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sirtuin1%20(sirt1)%20regulates%20the%20glycolysis%20pathway%20and%20decreases%20cisplatin%20chemotherapeutic%20sensitivity%20to%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=Cancer%20biology%20&%20therapy&rft.au=Yang,%20Xuewen&rft.date=2024-12-31&rft.volume=25&rft.issue=1&rft.spage=2365449&rft.pages=2365449-&rft.issn=1538-4047&rft.eissn=1555-8576&rft_id=info:doi/10.1080/15384047.2024.2365449&rft_dat=%3Cproquest_pubme%3E3067915152%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3067915152&rft_id=info:pmid/38865161&rft_doaj_id=oai_doaj_org_article_dfa44998f9694b6ba2e85c2352a75f53&rfr_iscdi=true |